




Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma



OCTOBER 11, 2024 | CONGRESS CENTER BASEL, SCHWEIZ

11:30 - 11:35 **WELCOME**
Shaji Kumar and Hermann Einsele

ROLE OF IMMUNOTHERAPY IN MM

Co-chairs: Hartmut Goldschmidt, Martin Gramatzki, and Shaji Kumar

11:35 - 11:45 **Frontline Therapy 2025**
Francesca Gay

11:45 - 11:55 **Role of Belamaf in the Future**
Katja Weisel

11:55 - 12:05 **Targets to Immunotherapy: Proteomics to predict outcome and drug resistance**
Jan Krönke

12:05 - 12:15 **Managing short-term TCE/CAR T cell toxicities – what did we learn?**
Marc Raab

12:15 - 12:25 **Late neurotoxicity after CAR T**
Sofie-Katrin Kadel

12:25 - 12:35 **Panel Discussion**

HOW TO OPTIMIZE T CELL ENGAGING THERAPIES

Co-chairs: Francesca Gay, Hans Salwender, and Niklas Zojer

12:35 - 12:45 **Role of MRD (MB.liquid biopsy) after Immunotherapy – when and for whom?**
Johannes Waldschmidt

12:45 – 12:55 **Vaccination post CAR T cell therapy: Facts and Expert Opinions**
Heinz Ludwig

12:55 - 13:05 **How to address EMD with T cell engaging therapies?**
Lisa Leypoldt

13:05 - 13:15 **Mechanisms of resistance to T cell engaging antibodies**
Niels Weinhold

13:15 - 13:25 **Should we measure Ag expression or screen for T cell functionality – how and when?**
Leo Rasche

13:25 - 13:35 **Treatment of relapse after CAR T**
Christoph Driessen

13:35 - 13:45 **Panel Discussion**

13:35 - 13:45 **BREAK**

THE FUTURE OF T CELL ENGAGING THERAPIES

Co-chairs: Shaji Kumar and Hermann Einsele

14:00 - 14:10	CAR-T in earlier lines: For everyone or for functional high-risk? Christof Scheid
14:10 - 14:20	Optimal Bridging strategies: What to do, what to avoid? Is Talquetamab an option? Maximilian Merz
14:20 - 14:30	CAR-T after CAR-T? Possible? Feasible? Effective? Monika Engelhardt
14:30 - 14:40	PI Therapy 2.0 - Can we apply Proteasome Inhibition to modulate Target Antigen expression and efficacy of T cell redirection strategies? Florian Bassermann
14:40 - 14:50	Novel constructs/concepts – Dual binding CAR-T cells, other strategies to improve CAR-T cells Michael Hudecek
14:50 - 15:00	CAR-T cell therapy for MM in 2024 Hermann Einsele
15:00 - 15:10	Panel Discussion
15:10	CLOSE

The International Myeloma Society gratefully acknowledges the following organizations for their support of the workshop:

PLATINUM

Johnson & Johnson

GOLD

 **Bristol Myers Squibb®**